Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/16—Emollients or protectives, e.g. against radiation

Definitions

• BACKGROUND Corns and calluses are examples of hyperkeratosis.
• Hyperkeratosis is hypertrophy of the stratum corneum (ie., outer layer of the skin) caused by excess production of keratinized tissue relative to shedding of keratinized tissue. Essentially, hyperkeratotic tissue forms where more stratum corneum is being made than is being lost. According to the Handbook of Nonprescription Drugs, Eighth
• corns and calluses are strikingly similar in one respect: each has a marked hypertrophy of the stratum corneum. Beyond this feature, however, there are marked differences.
• a corn (clavus) is a small, sharply demarcated, hyperkeratotic lesion having a central core. It is raised, has a yellowish gray color, and ranges from a few millimeters to one centimeter or more in diameter. The apex of the corn points inward and presses on the nerve endings in the dermis, causing pain.
• a callus is different from a corn in that it has no central core, has more diffuse thickening of the skin and generally occurs in different locations on the body.
• U.S. Patent 5,091 ,171 discloses generically, that amphoteric compositions containing the dimeric or polymeric forms of hydroxyacids may be useful in treating cosmetic conditions and dermatologic disorders in human and animals, including dry skin, dandruff, acne, keratoses, psoriasis, eczema, pruitus, age spots, lentigines, melasmas, wrinkles, warts, blemished skin, hyperpigmented skin, hyperkeratotic skin, inflammatory dermatoses, skin changes associated with aging and as skin cleaners.
• Patent 4,824,865 discloses that 2-hydroxyoctanoic acid, 2-ketooctanoic acid and their C2 to C& alkyl esters are useful in treating callous-forming disorders, notably palmar and plantar hyperkeratosis, including corns.
• a number of other agents have been taught for treating corns or calluses such as glacial acetic acid, lactic acid, salicylic acid, phenoxyacetic acid, zinc chloride, ascorbic acid, calcium pantothenate, cantharidin, podophyllum and bleomycin sulfate. It would be desirable, however, to provide undiscovered alternative methods as effective or even more so for treating corns and calluses.
• the present invention is directed towards a medicament for treating corns and calluses containing an effective amount of at least one saturated ⁇ -hydroxy fatty acid having 12 to 22 carbon atoms, or salts or esters thereof.
• the medicament can be in the form of a liquid preparation or a medicated device which contains the saturated ⁇ - hydroxy fatty acid.
• the amount of saturated ⁇ -hydroxy fatty acid in the liquid preparation can range from about 5 to about 25 percent by weight of the liquid preparation.
• the medicated device can comprise at least one saturated ⁇ -hydroxy fatty acid having 12 to 22 carbon atoms, or salts or esters thereof, admixed into a plaster preparation, wherein the plaster preparation is attached to a carrier.
• the saturated ⁇ -hydroxy fatty acid can be present in the plaster preparation in an amount ranging from about 15 to about 80 percent (%) by weight of the plaster preparation.
• the saturated ⁇ -hydroxy fatty acid is ⁇ -hydroxy palmitic acid.
• the ⁇ -hydroxy fatty acid has an even number of carbon atoms.
• the present invention is directed toward a method for treating corns and calluses, comprising contacting the affected area with the liquid preparation or the medicated device containing an effective amount of at least one saturated ⁇ -hydroxy fatty acid having 12 to 22 carbon atoms, or salts or esters thereof, to effect softening or loosening of the corn or callus for removal thereof.
• the present invention has the advantage of providing compounds which can rapidly penetrate corn and callus tissues to facilitate rapid softening or loosening thereof, for removal from the body.
• Saturated ⁇ -hydroxy fatty acids, salts or esters thereof suitable for use in the present method include ⁇ -hydroxy lauric acid (C-12), ⁇ -hydroxy myristic acid (C-14), ⁇ -hydroxy palmitic acid (C-16), ⁇ -hydroxy stearic acid (C-18), ⁇ -hydroxy arachidic acid (C-20) or ⁇ -hydroxy behenic acid (C-22).
• Suitable pharmacologically acceptable salts include various inorganic acids and bases such as ammonium salts, alkali metal salts, eg. sodium and potassium salts, and alkaline earth metal salts, eg. calcium and magnesium salts.
• Salts with organic bases may also be employed, eg. N-methylglucamine, lysine and arginine, as well as salts of organic and inorganic acids, eg. HCI, HBr, H2SO4, H 3 PO 4 , methanesulfonic acid, toluenesulfonic acid, maleic acid, fumaric acid and camphorsulfonic acid.
• Suitable esters include the C2 to C- ⁇ alkyl esters, diglyceride and triglyceride esters and mixtures thereof.
• liquid preparations includes liquid preparations and medicated devices.
• Typical liquid preparations include those pharmaceutical forms in which the compound is applied locally or topically by direct contact with the external surface to be treated.
• Conventional liquid pharmaceutical forms for this purpose include ointments, waxes, lotions, pastes, jellies, sprays, aerosols, colloidal suspensions and the like in aqueous or non- aqueous formulations.
• ointment refers to formulations including creams which are oleaginous, absorbative or water soluble, and include emulsion type bases such as petrolatum, lanolin, polyethylene glycols as well as mixtures thereof.
• Non-aqueous formulations include solutions containing solvents such as monoalcohols of from two to ten carbon atoms including ethanol and isopropanol, and diols such as ethylene glycol or propylene glycol.
• the liquid preparation can also include polymeric resins which upon evaporation of the solvent, will form films which hold the ⁇ -hydroxy fatty acid(s) against the corn or callus.
• the liquid preparation containing the ⁇ -hydroxy fatty acid compound can be administered by spraying, dabbing, swabbing or other means of applying the preparation to the corn or callus tissue.
• immediate device refers to a combination of at least one ⁇ -hydroxy fatty acid, or salts, esters or mixtures thereof in a suitable delivery system where the active ingredient is dissolved or dispersed in a vehicle affixed to the skin.
• One of the more common medicated devices include plaster preparations attached to a carrier or backing material.
• vehicle broadly refers to any inert medium in which the active ingredient is administered, including but not limited to film-solvents, plasters, carriers or binders for the active ingredient.
• plaster refers to any non-liquid vehicle which can be applied to the skin and which can hold an ⁇ -hydroxy fatty acid(s) against a corn or callus.
• Suitable plaster vehicles include plasters or preformed films based upon rubbers, acrylics, polysiloxanes, polyvinylalkylethers, gels or impregnated microporous membranes.
• plaster preparation refers to a preparation of at least one ⁇ -hydroxy fatty acid, or salts, esters or mixtures thereof in a plaster vehicle.
• the plaster preparation is self-adhering to the corn or callus.
• the plaster preparation can be cut to the size of the corn or callus and held in place with waterproof or water resistant tapes or bandages.
• the plaster preparation containing an ⁇ -hydroxy fatty acid(s) and the plaster vehicle is attached to a carrier to form a medicated device.
• the carrier or backing material can impart occlusive properties and dimensional strength to the plaster preparation.
• the carrier can also provide dimensional stability to the plaster preparation against disintegration and/or tearing by external forces, such as shear forces exerted on the plaster from normal handling or from rubbing of the limb afflicted with the corn or callus.
• the carrier can be selected from a wide range of materials, especially those which can promote occlusion and hydration of the corn or callus, such as moleskin, cotton, a resin-impregnated woven cloth, flexible polyvinyl chloride film or a flexible polyester film.
• the plaster preparation can be designed to be highly occlusive without the need for the carrier to possess substantial occlusive properties.
• the carrier can be attached to the plaster preparation by lamination techniques, by coextrusion or by bonding the carrier onto the plaster preparation using adhesives.
• the ⁇ -hydroxy fatty acid(s) are employed in amounts effective to treat the corn or callus tissue.
• the amount of ⁇ -hydroxy fatty acid(s) in a liquid can range from about 5 to about 25 percent (%) by weight, preferably from about 5 to about 15%.
• the amount of ⁇ -hydroxy fatty acid(s) can range from about 15 to about 80 percent, more preferably from about 30 to 50 percent.
• the medicament can be topically applied according to a regimen effective to soften or loosen the corn or callus tissue for removal thereof from the body. Generally, the medicament can be applied to the tissue one or two times daily or for intermittent intervals such as for two to three times per week until the corn or callus is softened or loosened sufficiently for removal.
• the corn or callus can be soaked in water or bathed before application of a medicament containing the ⁇ -hydroxy fatty acid.
• the guinea pig is used as a model because the guinea pig footpad is composed of hyperkeratotic tissue.
• Three Hartley guinea pigs are used per treatment group. Either the right or left rear callused footpad is treated, and the opposite footpad serves as the untreated control. Within a treatment group, the same footpad is treated on the same animal.
• a small cotton pledget is saturated with 200 ⁇ l of 12% w/w of an ⁇ -hydroxy fatty acid in a colloidian based vehicle and then applied once to the treated footpad.
• 0 no visible difference between treated and control footpads.
• 0.5 slight fine cracks in the callus of the treated footpads.
• the Keratolytic Index can range from zero to 20.
• a Kl of zero indicates that the callus is unaffected by the treatment.
• a Kl of 10 indicates a strong keratolytic effect within 72 to 96 hours.
• a Kl of 20 indicates an extremely strong keratolytic effect within 48 hours.
• the data above indicates that the ⁇ -hydroxy fatty acids of the prevent invention exhibit a Kl between 6.7 to 11.
• the ⁇ -hydroxy fatty acids demonstrate a strong keratolytic effect by clear separation of the stratum corneum over a portion of the treated footpad area within 3 to 4 days.
• salicylic acid the commercial standard, with a Kl of 2.4, exhibits only a moderate keratolytic effect and is significantly less effective than the ⁇ -hydroxy fatty acids of the present invention.

Landscapes

• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Toxicology (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Dermatology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines Containing Plant Substances (AREA)
• Fats And Perfumes (AREA)
• Medicinal Preparation (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=25472877

Family Applications (1)

Country Status (6)

Family Cites Families (3)

• 1993
  • 1993-08-20 WO PCT/US1993/007720 patent/WO1994005278A1/en not_active Application Discontinuation
  • 1993-08-20 AU AU50163/93A patent/AU5016393A/en not_active Abandoned
  • 1993-08-20 EP EP93920123A patent/EP0658108A1/de not_active Withdrawn
  • 1993-08-20 JP JP6507216A patent/JPH08500603A/ja active Pending
  • 1993-08-20 CA CA002143629A patent/CA2143629A1/en not_active Abandoned
  • 1993-09-01 MX MX9305345A patent/MX9305345A/es unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events